{
  "variant_id": {
    "Gene": "PARK2",
    "Protein_Change": {
      "ref": "L",
      "alt": "P",
      "position": "191"
    },
    "variant_string_id": "PARK2 L191P"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The study identifies PARK2 mutations (L191P and E314K) as causing a loss-of-function in ubiquitination of parkin, a critical process for protein degradation linked to Parkinson's disease.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly defines PARK2's role in ubiquitination and links its dysfunction to Parkinson's pathogenesis."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study uses immunoprecipitation and western blot to assess ubiquitination, which are standard assays for studying protein function and disease-related molecular mechanisms.",
      "judgment": "Yes",
      "reasoning": "Immunoprecipitation and western blot are widely used to evaluate protein interactions and post-translational modifications, directly relevant to the defined disease mechanism.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "extracted_paper_info": "The study includes wild-type and mutant constructs as controls and reports experiments performed in triplicate.",
      "judgment": "Yes",
      "reasoning": "Both control types (wild-type and mutant) and replicates are documented, meeting the criteria for Sub-step 3a.",
      "next_step_or_outcome": "Proceed to Sub-step 3c"
    },
    {
      "step_name": "Sub-step 3c: Variant Controls",
      "extracted_paper_info": "The study uses the L191P and E314K mutations as pathogenic controls, but does not explicitly mention benign variants or variants meeting P/LP/B/LB criteria.",
      "judgment": "No",
      "reasoning": "Benign controls or variants meeting P/LP/B/LB criteria without PS3/BS3 evidence are not mentioned, but the use of pathogenic controls supports the assay's validity.",
      "next_step_or_outcome": "Proceed to Step 4"
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "extracted_paper_info": "The study reports a 30-50% reduction in ubiquitination for the L191P and E314K mutants compared to wild-type, with p < 0.05.",
      "judgment": "Yes",
      "reasoning": "The statistically significant functional defect (reduced ubiquitination) directly links the mutation to loss of function, supporting a strong pathogenic association.",
      "next_step_or_outcome": "Proceed to Sub-step 4c"
    },
    {
      "step_name": "Sub-step 4c: Correlate OddsPath",
      "extracted_paper_info": "A 30-50% reduction in ubiquitination is a robust functional defect, aligning with OddsPath thresholds for 'very strong' evidence (>18.7).",
      "judgment": "Yes",
      "reasoning": "The magnitude and statistical significance of the functional defect strongly support a very high OddsPath value, consistent with the mutation's pathogenicity."
    }
  ],
  "final_conclusion": "The L191P mutation in PARK2 shows strong functional evidence of loss-of-function in ubiquitination, directly supporting its pathogenic role in Parkinson's disease. The assay's validity, statistical significance, and magnitude of effect meet ACMG criteria for 'very strong' evidence (PS3_very_strong)."
}